{"title":"FORMULATE AND EVALUATE THE ORAL DISPERSIBLE TABLET OF ANTIDIABETIC DRUG TENELIGLIPTIN","authors":"Arpana Maurya, D. Gupta, Munendra Mohan Varshaney","doi":"10.7897/2230-8407.1210165","DOIUrl":null,"url":null,"abstract":"Orodispersible tablets (ODTs) are novel drug delivery systems that have the potential to significantly affect conventional dosage forms in terms of patient compliance, convenience, bioavailability, and time to action. Despite the fact that significant research has gone into developing ODT formulations and technologies, in order to produce newer, more expense technologies and better items, more research is needed in these major destinations. Because of the availability of new technologies, as well as good market acceptance and patient compliance, the potential of dosage forms is attractive. Pharmaceutical companies can use ODTs for new product lines or first-to-market products, which is a factor in technology. With the continuing development of new pharmaceutical excipients, more unique ODT technologies are likely to occur soon. Method -For the orodispersible tablet optimized formulation, a direct compression method was used. Result: The pure dosage calibration curve was created by dissolving the medication in ethanol and measuring the absorbance with a UV spectrophotometer set at 243.5 nm. The value of the slope was 1.025. Light microscopy was used to predict the size of teneligliptin particles. The average length and breadth of drug particles were 2.10 µm and 1.14µm. In-vitro drug release study profile of formulation demonstrated around 71 % of the drug diffused in 60 min., while the formulation 85 % of the rug release in 60 min.","PeriodicalId":14413,"journal":{"name":"International Research Journal Of Pharmacy","volume":"89 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Research Journal Of Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7897/2230-8407.1210165","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Orodispersible tablets (ODTs) are novel drug delivery systems that have the potential to significantly affect conventional dosage forms in terms of patient compliance, convenience, bioavailability, and time to action. Despite the fact that significant research has gone into developing ODT formulations and technologies, in order to produce newer, more expense technologies and better items, more research is needed in these major destinations. Because of the availability of new technologies, as well as good market acceptance and patient compliance, the potential of dosage forms is attractive. Pharmaceutical companies can use ODTs for new product lines or first-to-market products, which is a factor in technology. With the continuing development of new pharmaceutical excipients, more unique ODT technologies are likely to occur soon. Method -For the orodispersible tablet optimized formulation, a direct compression method was used. Result: The pure dosage calibration curve was created by dissolving the medication in ethanol and measuring the absorbance with a UV spectrophotometer set at 243.5 nm. The value of the slope was 1.025. Light microscopy was used to predict the size of teneligliptin particles. The average length and breadth of drug particles were 2.10 µm and 1.14µm. In-vitro drug release study profile of formulation demonstrated around 71 % of the drug diffused in 60 min., while the formulation 85 % of the rug release in 60 min.